Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18237
Country/Region: Tanzania
Year: 2016
Main Partner: Deloitte Consulting Limited
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USAID
Total Funding: $13,697,663 Additional Pipeline Funding: $4,897,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,458,255
Care: TB/HIV (HVTB) $659,567
Care: Pediatric Care and Support (PDCS) $311,315
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $2,731,397
Treatment: Adult Treatment (HTXS) $7,781,590
Treatment: Pediatric Treatment (PDTX) $755,539
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 1,673
GEND_GBV Age/Sex: <10 Male 2017 1,540
GEND_GBV Age/Sex: 10-14 Female 2017 2,662
GEND_GBV Age/Sex: 10-14 Male 2017 1,875
GEND_GBV Age/Sex: 15-19 Female 2017 1,405
GEND_GBV Age/Sex: 15-19 male 2017 1,358
GEND_GBV Age/Sex: 20-24 Female 2017 1,067
GEND_GBV Age/Sex: 20-24 Male 2017 882
GEND_GBV Age/Sex: 25-49 Female 2017 1,359
GEND_GBV Age/Sex: 25-49 Male 2017 1,142
GEND_GBV Age/Sex: 50+ Female 2017 152
GEND_GBV Age/Sex: 50+ Male 2017 130
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 639
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 10,162
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 5,083
GEND_GBV Number of people receiving post-GBV care 2017 15,245
GEND_GBV Sum of Age/Sex Disaggregates 2017 7,750
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 38,918
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 47,410
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 240,230
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 86,180
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 412,738
HTS_TST Service Delivery Point (Facility): Inpatient 2017 13,998
HTS_TST Service Delivery Point (Facility): Other PITC 2017 9,715
HTS_TST Service Delivery Point (Facility): Outpatient 2017 152,485
HTS_TST Service Delivery Point (Facility): Pediatric 2017 77,784
HTS_TST Service Delivery Point (Facility): PMTCT 2017 158,756
HTS_TST Sum of Aggregated Age/Sex <15 2017 86,328
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 326,410
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 412,738
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,010
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,071
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 12,398
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 6,035
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 15
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 2
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 72
LAB_PT CD4: Number of laboratories that perform this testing 2017 2
LAB_PT CD4: Number of laboratories that perform this testing 2017 100
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 130
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 129
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 129
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 190
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 130
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 193
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 7
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 66
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 51
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 2
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 70
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 9
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program 2017 7
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 7
PMTCT_ART Already on ART at beginning of current pregnancy 2017 3,024
PMTCT_ART New on ART 2017 5,505
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 153,389
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 6,495
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 2,051
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 70
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 196
PMTCT_EID Sum of Infant Age disaggregates 2017 8,546
PMTCT_STAT By: Known positives at entry 2017 3,187
PMTCT_STAT By: Number of new positives identified 2017 5,801
PMTCT_STAT Number of new ANC and L&D clients 2017 161,476
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 153,389
PMTCT_STAT Sum of Positives Status disaggregates 2017 8,988
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 2,296
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 25
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 2,040
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 231
TB_SCREENDX Screen Result: Screened Positive for TB 2017 2,296
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 93,590
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 44,164
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 5,325
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 5,162
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 148,241
TX_CURR Aggregated Age/Sex: <15 Female 2017 5,193
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,585
TX_CURR Aggregated Age/Sex: 15+ Female 2017 100,184
TX_CURR Aggregated Age/Sex: 15+ Male 2017 45,089
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 156,051
TX_CURR Sum of Aggregated Age/Sex <15 2017 10,778
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 145,273
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 156,051
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,416
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,318
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 20,293
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 9,521
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 32,548
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 32,548
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 94,512
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 85,195
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 3,144
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 3,214
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 54,086
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 24,751
TX_PVLS Numerator: Indication: Routine 2017 29,412
TX_PVLS Numerator: Indication: Targeted 2017 55,783
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 3,493
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 3,545
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 60,025
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 27,449
TX_PVLS_den Denominator: Indication: Routine 2017 32,548
TX_PVLS_den Denominator: Indication: Targeted 2017 61,964
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 813
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 726
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 10,712
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,996
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 17,247
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 23,074
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,110
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 991
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14,295
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,678
Cross Cutting Budget Categories and Known Amounts Total: $1,314,185
Gender: Gender Based Violence (GBV) $300,047
GBV Prevention
Implementation
Capacity building
Post GBV Care
Gender: Gender Equality $964,138
Increase gender-equitable access to income and productive resources, including education
Equity in HIV prevention, care, treatment and support
Water $50,000